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Evaluation of an adjusted body weight based heparin protocol
Jenna Deininger, PharmD; Elizabeth Meisberger, PharmD, BCPS; Kris Howard, PharmD, BCPS
Parkview Regional Medical Center
Fort Wayne, Indiana

OBJECTIVE
Determine the efficacy and safety of a pharmacist-driven adjusted
body weight protocol for therapeutic intravenous (IV) heparin dosing
in patients of all weights in a community health system.

BACKGROUND
• Anticoagulation guidelines from the American College of Chest
Physicians, American College of Cardiology, and American Heart
Association support the use of weight-based therapeutic heparin.1,2
• Guidelines do not define what weight to use when dosing
therapeutic heparin.
• Previous studies suggest obese patients may require relatively lower
rates of weight-based heparin to obtain therapeutic anticoagulation
compared to normal weight patients.3,4,5
• Current institution protocols dose all therapeutic heparin infusions by
adjusted body weight.

RESULTS
Table 1
Demographics

Age, years
Male
Caucasian
Heparin Initiation
Location
Emergency
Intensive Care
Medical
Indication
DVT/PE†
ACS‡
Otherˠ

Normal
(n=91)
70.4
48 (52.7)
87 (95.6)

Overweight
(n=111)
65.7
72 (64.9)
101 (91)

BMI Class I
& II (n=143)
65.3
90 (62.9)
135 (94.4)

BMI Class III
(n=57)
56.8
30 (52.6)
50 (87.7)

39 (42.9)
21 (23.1)
31 (34)

52 (46.8)
18 (16.3)
41 (36.9)

61 (42.7)
26 (18.2)
56 (39.1)

30 (52.6)
8 (14)
19 (33.4)

35 (38.5)
32 (35.2)
24 (26.3)

32 (28.8)
36 (32.5)
43 (38.7)

39 (27.3)
73 (51)
31 (21.7)

25 (43.9)
15 (26.3)
17 (29.8)

Table 2

Percent Achieving 2 Therapeutic aPTTs
Consecutively and Time to Event
Normal
n (%)
Yes
35 (38.5)
No
56 (61.5)
Average time, hours
38.5
Overweight
Yes
38 (34.2)
No
73 (65.8)
Average time, hours
29.6
BMI Class I and II
Yes
57 (39.9)
No
86 (60.1)
Average time, hours
32.9
BMI Class III
Yes
15 (26.3)
No
42 (73.7)
Average time, hours
28.8

†Deep vein thrombosis/pulmonary embolism (goal aPTT 55-80), ‡Acute coronary syndromes (goal aPTT 50-70), ˠ
Other (goal aPTT 50-70)
*Unless otherwise stated, all numbers represented as n (%)

Figure 1

METHODS
• Study design: Retrospective chart review of patients who received
pharmacist-dosed therapeutic IV heparin infusion, including a bolus.
Subjects evaluated in groups divided by body mass index (BMI) as
defined by the World Health Organization (WHO). Data included
from May 2019 through August 2019.
• Inclusion criteria: Patients with at least one activated partial
thromboplastin time (aPTT) drawn 6 hours after heparin initiation.
• Exclusion criteria: Patients who received heparin prior to arrival at
the study site, those receiving thrombolytics prior to heparin
initiation, or those on heparin with Impella or neurologic conditions.
• Primary outcome: Percent of initial aPTTs in therapeutic range at
least 6 hours after heparin initiation
• Secondary outcomes:
• Percent of aPTTs in therapeutic range for 72 hours after heparin
initiation
• Percent of patients with two consecutive therapeutic aPTTs
• Time to two consecutive therapeutic aPTTs
• Number of dose changes within 72 hours of heparin initiation
• Percent of patients requiring additional heparin boluses
• Number of patients with two consecutive aPTTs >95 seconds
• Time to next aPTT following an aPTT >110 seconds
• Safety outcomes:
• Incidence of minor bleeding as defined by the Bleeding Academic
Research Consortium (BARC)
• Incidence of major bleeding as defined by BARC criteria
• Percent of patients with an aPTT >110 seconds
• Incidence of new thrombosis after heparin initiation

Figure 2

Table 2

RESULTS
Outcomes
• 41.3% of WHO Class I and II obesity (BMI ≥30-40) patients were
therapeutic at the first aPTT level drawn at least 6 hours after
therapeutic heparin was initiated.
• WHO Class III obesity (BMI >40) patients had the lowest rates of
initial therapeutic aPTTs at 19.3%.
• On average, WHO Class III patients required 2.9 rate changes to
become therapeutic compared to 2.5 rate changes in other groups.
• Normal weight and overweight patients had the most aPTTs >95
seconds consecutively (6.6% and 5.4% respectively) compared to
WHO Class I and II, and Class III patients (2.1% and 0%).
• Following an aPTT >110 seconds, the time to next aPTT was an
average of 8 hours.
Safety
• Incidence of minor bleeding is likely limited by under reporting.
• Only 2.7% of patients experienced bleeding requiring transfusion
while on heparin, and no deaths due to bleeding occurred.
• 16.2% of patients had at least one aPTT >110 seconds.
• No incidence of new thrombosis after heparin initiation was found.

CONCLUSIONS
• The current protocol is effectively managing patients of all weight
groups receiving therapeutic IV heparin, however some
improvements could be made in the heaviest patients.
• Findings suggest patients with a BMI ≥40 may benefit from the
utilization of a higher dosing regimen to obtain more therapeutic
aPTTs.
• Studies utilizing actual body weight based dosing for therapeutic
heparin have demonstrated a risk for bleeding similar to that of this
study.3,5
• Use of actual body weight may be a more appropriate approach for
dosing therapeutic heparin in patients with a BMI ≥40.
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